The GABA-glutamate connection in schizophrenia: Which is the proximate cause?

Biochemical Pharmacology

Volumn 68, Issue 8, 2004, Pages 1507-1514

  Coyle, Joseph T ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

d Serine; GABA; Glutamate; Glycine B receptor; NMDA receptor; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; CARRIER PROTEIN; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

BRAIN CORTEX; BRAIN ELECTROPHYSIOLOGY; BRAIN REGION; COGNITIVE DEFECT; HUMAN; INTERNEURON; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA;

EID: 4644228386     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.07.034     Document Type: Note

References (88)

1. S.H. Snyder Dopamine receptors, neuuroleptics, and schizophrenia Am J Psychiatr 138 1981 460 464
2. W.T. Carpenter Jr., D.W. Heinrichs, and A.M. Wagman Deficit and nondeficit forms of schizophrenia: the concept Am J Psychiatr 145 1988 578 583
3. T.D. Cannon, T.G. van Erp, C.E. Bearden, R. Loewy, P. Thompson, and A.W. Toga Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions Schizophr Bull 29 2003 653 669
4. Meltzer HY, Deutch AY. Neurochemistry of schizophrenia. In: Siegel GJ, editor. Basic neurochemistry: molecular, cellular and medical aspects, 6th ed., Philadelphia: Lippicott-Rowen; 1998. p. 1053-72.
5. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. 2001;25:1-27.
6. P.J. Harrison, and M.J. Owen Genes for schizophrenia? Recent findings and their pathophysiological implications Lancet 61 2003 417 419
7. E.D. Bird, E.G. Spokes, J. Barnes, A.V. Mackay, L.L. Iversen, and M. Shepherd Glutamic-acid decarboxylase in schizophrenia Lancet 1 1978 156
8. E.G. Spokes, N.J. Garrett, and L.L. Iversen Differential effects of agonal status on measurements of GABA and glutamate decarboxylase in human post-mortem brain tissue from control and Huntington's chorea subjects J Neurochem. 33 1979 773 778
9. A.J. Cross, T.J. Crow, and F. Woen Gamma-aminobutyric acid in the brain in schizophrenia Lancet 1 1979 560 561
10. D.A. Lewis, D.W. Volk, and T. Hashimoto Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction Psychopharmacology 174 2003 143 150
11. M.S. Todtenkopf, and F.M. Benes Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain Synapse 29 1998 323 332
12. S. Akbarian, J.J. Kim, S.G. Potkin, J.O. Hagman, A. Tafazzoli, and W.E. Bunney Jr. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics Arch Gen Psychiatr 52 1995 258 266
13. D.W. Volk, M.C. Austin, J.N. Pierri, A.R. Sampson, and D.A. Lewis Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia Arch Gen Psychiatr 57 2000 237 245
14. K. Mimics, F.A. Middleton, A. Marquez, D.A. Lewis, and P. Levitt Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex Neuron 28 2000 53 67
15. A. Guidotti, J. Auta, J.M. Davis, V. Di-Giorgi-Gerevini, Y. Dwivedi, and D.R. Grayson Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study Arch Gen Psychiatr 57 2000 1061 1069
16. M.P. Vawter, J.M. Crook, T.M. Hyde, J.E. Kleinman, D.R. Weinberger, and K.G. Becker Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study Schizophr Res. 58 2002 11 20
17. T. Hashimoto, D.W. Volk, S.M. Eggan, K. Mimics, J.N. Pierri, and Z. Sun Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia J Neurosci. 16 2003 6315 6326
18. G.P. Reynolds, C. Czudek, and H.B. Andrews Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia Biol Psychiatr 27 1990 1038 1044
19. M.D. Simpson, P. Slater, J.F. Deakin, M.C. Royston, and W.J. Skan Reduced GABA uptake sites in the temporal lobe in schizophrenia Neurosci Lett. 107 1989 211 215
20. M.D. Simpson, P. Slater, and J.F. Deakin Comparison of gl7utamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia Biol Psychiatr 44 1998 423 427
21. D.W. Volk, M.C. Austin, J.N. Pierri, A.R. Sampson, and D.A. Lewis GABA transporter-1 mRNA in prefrontal cortex in schizophrenia: decreased expression in a subset of neurons Am J Psychiatr 158 2001 256 265
22. T.U. Woo, R.E. Whitehead, D.S. Melchitzky, and D.A. Lewis A subclass of prefrontal gama-aminobutyric acid axon terminals are selectively altered in schizophrenia Proc Natl Acad Sci USA 28 1998 5341 5346
23. D.W. Volk, J.N. Pierri, J.M. Fritschy, S. Auh, A.R. Sampson, and D.A. Lewis Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cells inputs to pyramidal neurons in schizophrenia Cereb Cortex 12 2002 1063 1070
24. 3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics Life Sci. 40 1987 259 266
25. F.M. Benes, S.L. Vincent, A. Marie, and Y. Khan Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects Neuroscience 75 1996 1021 1031
26. F.M. Benes, Y. Khan, S.L. Vincent, and R. Wickramasinghe Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain Synapse 22 1996 338 439
27. B. Dean, T. Hussain, W. Hayes, E. Scarr, S. Kitsoulis, and C. Hill Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex J Neurochem. 72 1999 1593 1599
28. F.M. Benes, R. Wickramasinghe, S.L. Vincent, Y. Khan, and M. Todtenkopf Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain Brain Res 755 1997 121 129
29. F. Impagnatiello, A.R. Guidotti, C. Pesold, Y. Dwivedi, H. Canmcho, and M.G. Pisu A decrease of reeling expression as a putative vulnerability factor in schizophrenia Proc Natl Acad Sci. 95 1998 15718 15723
30. S. Akbarian, A. Vinuela, J.J. Kim, S.G. Potkin, W.E. Bunney Jr., and E.G. Jones Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development Arch Gen Psychiatr 50 1993 178 187
31. M.A. Rodriguez, H.J. Caruncho, E. Costa, C. Pesold, W.S. Liu, and A. Guidotti In Patas monkey, glutamic acid decarobxylase-67 and reelin mRNA coexpression varies in a manner dependent on layers and cortical areas J Comp Neurol. 451 2002 279 288
32. S.H. Fatemi, J.A. Earle, and T. McMenomy Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression Mol Psychiatr 5 2000 654 663
33. M.B. Knable, B.M. Bard, M.J. Webster, J. Meador-woodruff, and E.F. Torrey Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley neuropathology Consortium Mol Psychiatr 9 2004 609 620
34. S.L. Eastsood, and P.J. Harrison Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis Mol Psychiatr 8 2003 821 831
35. S.H. Fatemi, J.L. Kroll, and J.M. Stary Altered levels of Reelin and its isoforms in schizophrenia and mood disorders Neuroreport 12 2001 3209 3215
36. A. Akahane, H. Kunugi, H. Tanaka, and S. Nanko Association analysis of polymorphic CGG repeat in 5′ UT‰ of the reelin and VLDLR genes with schizophrenia Schizophr Res. 58 2002 37 41
37. O.M. Wolkowitz, and D. Pickar Benzodiazepines in the treatment of schizophrenia: a review and reappraisal Am J Psychiatr 148 1991 714 726
38. E.D. Luby, B.D. Cohen, G. Rosenbaum, J.S. Gottlieb, and R. Kelley Study of a new schizophrenomimetic drug; sernyl AMA Arch Neurol Psychiatr 81 1959 363 369
39. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am J Psychiatr 148 1991 1301 1308
40. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, and J.D. Bremner Arch Gen Psychiatr 51 1994 199 214
41. J.W. Newcomer, N.B. Farber, V. Jevtovic-Todorovic, G. Selke, A.K. Melson, and T. Hershey Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis Neuropsychopharmacology 20 1999 106 118
42. A.K. Malhortra, C.M. Adler, S.D. Kennison, I. Elman, D. Pickar, and A. Breier Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: a study with ketamine Biol Psychiatr 42 1997 664 668
43. M.T. Avila, M.A. Weiler, A.C. Lahti, C.A. Tamminga, and G.K. Thaker Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia Am J Psychiatr 159 2002 1490 1496
44. F.X. Vollenweider, P. Vontobel, I. Oye, D. Hell, and K.L. Leenders Effects of 9S-ketamine on striatal dopamine: a [11C] raclopride PET study of a model psychosis in humans J Psychiatr Res. 34 2000 35 43
45. L.S. Kegeles, D. Martinez, L.D. Kochan, D.R. Hwang, Y. Huang, and O. Mawlawi NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans Synapse 43 2002 19 29
46. D.L. Braff, M.A. Geyer, and N.R. Swerdlow Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies Psychophannacology 156 2001 234 258
47. D. Umbricht, R. Roller, F.X. Vollenweider, and L. Schmid Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers Biol Psychiatr 1 2002 400 406
48. J.T. Coyle, and G. Tsai The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia Psychopharmacology 174 2004 32 38
49. R. Bergeron, T.M. Meyer, J.T. Coyle, and R.W. Greene Modulation of N-methyl-d-aspartate receptor function by glycine transport Proc Natl Acad Sci USA 95 1998 15730 15734
50. J.P. Mothet, A.T. Parent, H. Wolosker, R.O. Brady Jr., D.J. Linden, and C.D. Ferris d-Serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor Proc Natl Acad Sci USA 97 2000 4926 4931
51. I. Chumakov, M. Blumenfeld, O. Guerassimenko, L. Cavarec, M. Palicio, and H. Abderrahim Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia Proc Natl Acad Sci USA 99 2002 13675 13680
52. X. Wang, G. He, N. Gu, J. Yang, J. Tang, and Q. Chen Association of G72/G30 with schizophrenia in the Chinese population Biochem Biophys Res Commun. 319 2004 1281 1286
53. D. Hall, J.A. Gogos, and M. Karayiorgou The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations Genes Brain Behav. 4 2004 240 248
54. K. Hashimoto, T. Fukushima, E. Shimizu, N. Komatsu, H. Watanabe, and N. Shinoda Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia Arch Gen Psychiatr 60 2003 572 576
55. J.T. Coyle The nagging question of the function of N- acetylaspartylglutamate Neurobiol Dis. 4 1997 231 238
56. Bergeron R, Coyle JT, Tsai G, Greene RW. NAAG reduces NMDA receptor current in CA1 hippocampel pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology, in press.
57. G. Tsai, L.A. Passani, B.S. Slusher, R. Carter, L. Baer, and J.E. Kleinman Abnormal excitatory neurotransmitter metabolism in schizophrenic brains Arch Gen Psychiatr 52 1995 829 836
58. Y. Hakak, J.R. Walker, C. Li, W.H. Wong, K.L. Davis, and J.D. Buxbaum Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia Proc Natl Acad Sci USA 98 2001 4746 4751
59. C.A. Semple, R.S. Devon, S. Le Hellard, and D.J. Porteous Identification of genes from a schizophrenia-linked translocation breakpoint region Genomics 73 2001 123 126
60. R. Schwarcz, A. Rassoulpour, H.Q. Wu, D. Medoff, C.A. Tamminga, and R.C. Roberts Increased cortical kynurenate content in schizophrenia Biol Psychiatr 50 2001 521 530
61. S. Erhardt, K. Blennow, C. Nordin, E. Skogh, L.H. Lindstrom, and G. Engberg Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia Neurosci Lett 313 2001 96 98
62. C.L. Miller, I.C. Llenos, J.R. Dulay, M.M. Barillo, R.H. Yolken, and S. Weis Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia Neurobiol Dis. 15 2004 618 629
63. J.H. Meador-Woodruff, S.M. Clinton, M. Beneyto, and R.E. McCullumsmith Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia Ann NY Acad Sci. 1003 2003 75 93
64. K. Toyooka, S. Iritani, T. Makifuchi, O. Shirakawa, N. Kitamura, and K. Maeda Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia J Neuroochem. 83 2002 797 806
65. E.S. Emamian, M. Karayiorgou, and J.A. Gogos Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia J Neurosci. 24 2004 1561 1564
66. C.S. Weickert, R.E. Straub, B.W. McClintock, M. Matsumoto, R. Hashimoto, and T.M. Hyde Human dysbindin (DTNBPl)gene expression in noimal brain and in schizophrenic prefrontal cortex and midbrain Arch Gen Psychiatr 61 2004 544 555
67. P.J. Harrison, A.J. Law, and S.L. Eastwood Glutamate receptors and transporters in the hippocampus in schizophrenia Ann NY Acad Sci. 1003 2003 94 101
68. H. Stefansson, V. Steinthorsdottir, T.E. Thorgeirsson, J.R. Gulcher, and K. Stefansson Neuregulin 1 and schizophrenia Ann Med. 36 2004 62 71
69. R. Hashimoto, R.E. Straub, C.S. Weickert, T.M. Hyde, J.E. Kleinman, and D.R. Weinberger Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia Mol Psychiatr 9 2004 299 307
70. D.C. Goff, G. Tsai, D.S. Manoach, and J.T. Coyle Dose-finding trial of d-cyctoserine added to neuroleptics for negative symptoms in schizophrenia Am J Psychiatr 152 1995 1213 1215
71. D.C. Goff, G. Tsaig, J. Levitt, E. Amico, D. Manoach, and D.A. Schoenfeld A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch Gen Psychiatr 56 1999 21 27
72. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D.C. Javitt Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am J Psychiatr 159 2002 480 482
73. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, A. Horowitz, and D. Kelly Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia Br J Psychiatr 169 1996 610 617
74. D.C. Javitt, G. Silipo, A. Cienfuegos, A.M. Shelley, N. Bark, and M. Park Adjunctive high-dose glycine in the treatment of schizophrenia Int J Neuropsychopharmacol. 4 2001 385 391
75. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch Gen Psychiatr 56 1999 29 36
76. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J.T. Coyle d-Serine added to antipsychotics for the treatment of schizophrenia Biol Psychiatr 44 1998 1081 1089
77. G. Tsai, H.Y. Lane, P. Yang, M.Y. Chong, and N. Lange Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia Biol Psychiatr 5 2004 452 456
78. A.E. Evins, S.M. Fitzgerald, L. Wine, R. Rosselli, and D.C. Goff Placebo-controlled trial of glycine added to clozapine in schizophrenia Am J. Psychiatr 157 2000 826 828
79. G.E. Tsai, P. Yang, L.C. Chung, I.C. Tsai, C.W. Tsai, and J.T. Coyle d-Serine added to clozapine for the treatment of schizophrenia Am J Psychiatr 156 1999 1822 1825
80. S.G. Potkin, Y. Jin, B.G. Bunney, J. Costa, and B. Gulasekaram Effect of clozapine and adjuynctive high-dose glycine in treatment-resistant schizophrenia Am J Psychiatr 156 1999 145 147
81. D.C. Goff, G. Tsai, D.S. Manoach, J. Hood, D.G. Darby, and J.T. Coyle d-Cycloserine added to clozapine for patients with schizophrenia Am J Psychiatr 153 1996 1628 1630
82. D.C. Goff, D.C. Henderson, A.E. Evins, and E. Amico A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia Biol Psychiatr 45 1999 512 514
83. B. Moghaddam, and M.E. Jackson Glutamatergic animal models of schizophrenia Ann NY Acad Sci. 1003 2003 131 137
84. H.G. Grunze, D.G. Rainnie, M.E. Hasselmo, E. Barkai, E.F. Hearn, and R.W. McCarley NMDA-dependent modulation of CAl local circuit inhibition J Neurosci. 16 1996 2034 2043
85. J.W. Olney, J. Labruyere, G. Wang, D.F. Wozniak, M.T. Price, and M.A. Sesma NMDA antagonist neurotoxicity: mechanism and prevention Science 254 1991 1515 1518
86. Q. Li, S. Clark, D.V. Lewis, and W.A. Wilson NMDA receptor antagonists disinhibit rat posterior cingulated and retrosplenial cortices: a potential mechanism of neurotoxicity J Neurosci. 22 2002 3070 3080
87. L. Paulson, P. Martin, A. Persson, C.L. Nilsson, E. Ljung, and A. Westman-Brinkmalm Comparative genome- and proteome analysis of cerebral cortex from MK-801-rreated rats J Neurosci Res. 71 2003 526 533
88. S. Heckers, S.L. Rauch, D. Goff, C.R. Savage, D.L. Schacter, and A.J. Fischman Impaired recruitment of the hippocampus during conscious recollection in schizophrenia Nat Neurosci. 4 1998 318 323